Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rucaparib Approved for Ovarian Cancer.

Cancer discovery - 1 Feb 2017

Abstract excerpt

The FDA approved the PARP inhibitor rucaparib to treat women with advanced ovarian cancer who have already been treated with at least two chemotherapies and have a BRCA1 or BRCA2 gene mutation identified by an approved companion diagnostic test. The agency also gave a nod to the FoundationFocus CDxBRCA test to detect BRCA alterations.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Drug Approval

Share to Indoles

Share to Multicenter Studies as Topic

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Identifiers

PMID: 28057616
DOI: 10.1158/2159-8290.CD-NB2016-164

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rucaparib Approved for Ovarian Cancer.PMID 28057616Read ↗

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancerSemantic proximity Read ↗

Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation: a systematic review and meta-analysis of phase III randomized clinical trials.Semantic proximity Read ↗

PARP Inhibitors for Cancer Therapy.Semantic proximity Read ↗

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer.Semantic proximity Read ↗

Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.Semantic proximity Read ↗

Evaluation of Rucaparib and Companion Diagnostics in the PARP Inhibitor Landscape for Recurrent Ovarian Cancer TherapySemantic proximity Read ↗

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Semantic proximity Read ↗

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.Semantic proximity Read ↗

New Therapies for Ovarian Cancer.Semantic proximity Read ↗

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid TumorsSemantic proximity Read ↗

PARP inhibitors: a tsunami of indications in different malignancies.Semantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: A ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.